Feed / MDLN

Medline Inc.

MDLN

Healthcare · 32.12 -5.6% today

Isolated · not yet confirmedMarket checked 11 Sept, 10:35 GMT-4

Market read

Medline Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.

Company-5.6% todayVolume comparison unavailable
Market group0 of 2 activeMedical Devices · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Tariff refunds and sales growth lifted Medline Brand Segment Adjusted EBITDA, while tariffs raised import costs and headcount investments raised compensation expense.

Invalidation: The isolated read changes if MDLN's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Instruments & Supplies

No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Tariff refunds and sales growth lifted Medline Brand Segment Adjusted EBITDA, while tariffs raised import costs and headcount investments raised compensation expense.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods3
Price observations183
Usable filing statements112
Verified relationships8
Evidence supporting the case
  • Latest annual revenue changed +11.5% year over year.
  • Operating cash flow covered net income at 1.50x in the latest annual period.
Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position
  • P/E is 55% below the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 45% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

32.39
6m-23.6%12m24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2023-12-31$23.2B
2024-12-31$25.5B+9.8%
2025-12-31$28.4B+11.5%$-0.01

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 3 filings
For the six months ended June 28, 2025, net cash used in financing activities was primarily driven by distribution to partners of $303 million, repayment for long-term borrowings of $19 million, and Class B Unit repurchases of $15 million.
10-Q · Aug 5, 2026
Input and raw-material costsmixed · 3 filings
Selling, General, and Administrative Expenses SG&A expenses for the six months ended June 27, 2026 increased $380 million, or 17.7%, to $2,523 million, compared to $2,143 million for the respective period in 2025, primarily due to $248 million of higher compe…
10-Q · Aug 5, 2026
Tariffs and trade policymixed · 3 filings
Changes in working capital resulted in net cash used of $324 million, which is primarily driven by an increase in other assets of $279 million related to the IEEPA tariff refund receivable, and an increase in trade accounts receivable of $148 million due to s…
10-Q · Aug 5, 2026
Capital investment and capacitymixed · 2 filings
For the six months ended June 28, 2025, net cash used in investing activities was primarily driven by net capital expenditures of $208 million and payments for asset acquisitions of $33 million.
10-Q · Aug 5, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 0.9× · EV/sales 1.3×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Fewer than 4 annual revenue periods; too little history to scaffold scenarios.

Price action

How the market is pricing the story

32.12-5.6% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 10:35 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for MDLN. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for MDLN. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind MDLN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ECLEcolab Inc.supplierFeb 25, 2026

During 2024, we acquired the global surgical solutions business of Ecolab, Inc., including industry-leading Microtek product lines (“Microtek”), and Sinclair Dental Co.

CAHCardinal Health, Inc.distributorFeb 25, 2026

Additionally, other distributors of med-surg products similarly connect the fragmented supplier and provider bases and aggregate inventory from suppliers to deliver products to customers, such as McKesson, Cardinal Health, Owens & Minor, and Henry Schein.

Depended on by

AVNS15.0% of AVNScustomerFeb 24, 2026

In the year ended December 31, 2025, sales to Medline Industries accounted for approximately 12% of consolidated net sales.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

MDLN is currently a Early Follower in the organic co-movement group Medical Devices. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.